Sandra Boenisch - 06 Jan 2026 Form 4 Insider Report for ANAVEX LIFE SCIENCES CORP. (AVXL)

Reporting relationship: PFO & Treasurer
Issuer ticker: AVXL
Reported as of: 06 Jan 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 09 Jan 2026, 17:26:26 UTC
Prior SEC filing: 03 Oct 2025
Source filing: View source filing
Reporting owner signature: /s/ Sandra Boenisch

Key filing fact

Sandra Boenisch filed Form 4 for ANAVEX LIFE SCIENCES CORP. (AVXL) on 09 Jan 2026.

Key facts

This page summarizes Sandra Boenisch's Form 4 filing for ANAVEX LIFE SCIENCES CORP. (AVXL).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 09 Jan 2026, 17:26.

Change

Previous filing in this sequence was filed on 03 Oct 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001655366 Primary reporting owner

Boenisch Sandra

Relationship: PFO & Treasurer
Address: 650 5TH AVENUE, 20TH FLOOR, NEW YORK
Signature: /s/ Sandra Boenisch
Signature date: 09 Jan 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AVXL transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +12,500
Change %
Price: $0.000000
Shares after: 12,500
Date: 06 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 12,500
Exercise price: $8.58
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

On March 31, 2025, the reporting person was granted an option to purchase 50,000 shares of common stock. The option vests in four equal tranches based on four performance milestones, one of which was a second regulatory dialogue for blarcamesine. The performance criteria for this milestone was met, resulting in vesting of the option as to 12,500 shares.